Santhera Update

SNT-317 (omigapil) in Congenital Muscular Dystrophies

Santhera, a Swiss pharmaceutical company, released financial updates for 2008 with forecast on its pharmaceutical focus for next year. Omigapil is a drug licensed by Santhera for treatment in the CMDs.

Preclinical work is ongoing internally in preparation of the clinical Phase II/III development.  External clinical development (clinical trials) has been postponed to support Santhera’s current focus on the core programs. The EMEA and FDA have both granted orphan drug designation to omigapil in the 2 most common subtypes of CMD.

This entry was posted in Research News. Bookmark the permalink. Both comments and trackbacks are currently closed.
  • Congenital Muscular Dystrophy

    A group of diseases causing muscle weakness at birth. Several defined genetic mutations cause muscles to break down faster than they can repair or grow. A child with CMD may have various neurological or physical impairments. Some children never gain the ability to walk, while others lose the ability as they grow older. Learn more...

  • Register Now!